Liposome Patents (Class 424/9.321)
-
Patent number: 11446402Abstract: The present invention relates to a composition for material delivery, including exosome mimetics derived from red blood cells, and a use thereof and the composition for material delivery according to an exemplary embodiment of the present invention includes exosome mimetics derived from red blood cells, which are capable of being loaded with a drug, a radioactive material, or a fluorescent material, and thus may be usefully utilized for a drug delivery use, a cell labeling use, a contrast medium, or the like, and when the composition for material delivery according to an exemplary embodiment of the present invention is used, treatment and diagnosis may be simultaneously performed.Type: GrantFiled: October 31, 2019Date of Patent: September 20, 2022Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Byeong Cheol Ahn, Seung Hyun Son, Prakash Gangadaran
-
Patent number: 11400049Abstract: The disclosure relates generally to compositions comprising pegylated liposomal formulations of apelin for the treatment of cardiovascular-related diseases.Type: GrantFiled: October 19, 2017Date of Patent: August 2, 2022Assignee: Avive, Inc.Inventor: Jayakumar Rajadas
-
Patent number: 11246949Abstract: Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the compounds can be used MRI paraCEST contrast agents.Type: GrantFiled: May 11, 2012Date of Patent: February 15, 2022Assignee: The Research Foundation for The State University of New YorkInventors: Janet R. Morrow, Pavel Tsitovich, Sarina Dorazio, Abiola Olatunde
-
Patent number: 11207348Abstract: A nanotherapeutic having platinum complexes encapsulated by a nanoformulation containing at least one spinel ferrite of formula CuFe2O4, NiFe2O4, CoFe2O4, and MnFe2O4 deposited on mesoporous silica. A method of preparing the nanotherapeutic that involves mixing a metal(II) salt and a Fe(III) salt with the mesoporous silica nanoparticles to form a powdery mixture, calcining the powdery mixture to form the nanoformulation, and mixing the nanoformulation with the platinum complex. A method for treating cancer with the nanotherapeutic.Type: GrantFiled: April 25, 2019Date of Patent: December 28, 2021Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: B. Rabindran Jermy, Vijaya Ravinayagam, Abdulhadi Baykal
-
Patent number: 11116854Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: GrantFiled: January 29, 2021Date of Patent: September 14, 2021Assignee: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Patent number: 10961199Abstract: The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C5)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK? is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.Type: GrantFiled: December 6, 2013Date of Patent: March 30, 2021Assignee: 3B PHARMACEUTICALS GMBHInventors: Frank Osterkamp, Christiane Smerling, Ulrich Reineke, Christian Haase, Jan Ungewiß
-
Patent number: 9532950Abstract: The present invention provides a liposome having excellent lung migration ability that had not existed hitherto, by including GALA or Chol-GALA in the liposome. Furthermore, by using the liposome, a pulmonary delivery carrier having a stronger knockdown effect of siRNA when compared to existing carriers is provided.Type: GrantFiled: March 13, 2012Date of Patent: January 3, 2017Assignees: National University Corporation Hokkaido University, Taiho Pharmaceutical Co., Ltd.Inventors: Kenji Kusumoto, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Taichi Ishitsuka
-
Patent number: 9408890Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.Type: GrantFiled: January 22, 2014Date of Patent: August 9, 2016Assignees: The Charles Stark Draper Laboratory, Inc., The Massachusetts Institute of Technology, University of California, Santa Barbara (UCSB), University of Massachusetts Medical SchoolInventors: James Comolli, Jose Trevejo, Ram Sasisekharan, Zachary Shriver, Karthik Viswanathan, Deborah Fygenson, Robert Finberg, Jennifer Wang
-
Patent number: 9005582Abstract: A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.Type: GrantFiled: December 20, 2012Date of Patent: April 14, 2015Assignees: University of North Carolina at Greensboro, United Arab Emirates UniversityInventor: Yousef Haik
-
Patent number: 9005583Abstract: There is provided a novel chain-end functionalized PEO of formulas (I) to (IV) prepared via living anionic polymerization and chain-end functionalization, as well as a simple method of preparing nano-sized transition metal or metal salt particles using the same, which can be readily stabilized even in an aqueous medium. The water-soluble PEO-based polymers having various functional groups (including a drug group such as vitamin and anti-cancer agent) and the process of preparing nano-sized transition metal or metal salt particles using the same can be advantageously used in the development of new materials for drug delivering system and imaging, e.g., a contrast agent and an anti-cancer agent simultaneously.Type: GrantFiled: July 6, 2006Date of Patent: April 14, 2015Assignee: Youl Chon Chemical Co., Ltd.Inventors: Jungahn Kim, Kwang Ung Kim, Seung Sang Hwang, Soon Man Hong, Soonjong Kwak, Joon Hyeong Park, Ji Hee Kim, Dong Youn Shin, Soon Geun Hwang, Jang Seop Kim, Han Wook Ryu
-
Publication number: 20150064115Abstract: Novel liposomal nanoparticle that has been engineered to be particularly useful for the delivery of compounds to cells found in the peripheral nervous system, and to endothelial cells that form the blood brain barrier. These nanoparticles are intended to be useful for the delivery of compounds suitable for therapeutic purposes and imaging contrast agents that may not otherwise gain access to neuronal axons, or glial cells regions of the brain. Particularly advantageous for the purpose of targeting neural cells, endothelial cells of the blood vessels and epithelial cells of the choroid plexus that serve the brain is the inclusion, in the nanoparticles of cholesterol that surprisingly increases the affinity of the nanoparticles for such as Schwann cells, glial cells, and the like. Image contrast agents, such as those suitable for use in MRI techniques may also be delivered to neural cells, including of the peripheral nervous system.Type: ApplicationFiled: March 6, 2013Publication date: March 5, 2015Inventors: Ana M. Ashizawa, Lucia Notterpek, Tetsuo Ashizawa
-
Patent number: 8951501Abstract: A noninvasive thermometry monitoring system for determining a temperature of tissue to which hyperthermia treatment is administered is disclosed. The monitoring system may incorporate magnetic nanoparticles having known moments such that once exposed to an alternating magnetic field, the magnetic nanoparticles increase in temperature. Imaging systems can disclose the magnetic nanoparticles within a patient. The temperature of the magnetic nanoparticles can be determined by comparing the magnetic nanoparticle with known temperatures for that type of magnetic nanoparticle. The image of the magnetic nanoparticles may be compared with surrounding tissue to determine the temperature of the surrounding tissue that is exposed to hyperthermia treatment.Type: GrantFiled: March 26, 2012Date of Patent: February 10, 2015Assignees: University of North Carolina at Greensboro, United Arab Emirates UniversityInventor: Yousef Haik
-
Patent number: 8945512Abstract: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a paramagnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium (111), thulium (III), ytterbium (III) and europium (111).Type: GrantFiled: April 6, 2004Date of Patent: February 3, 2015Assignee: Bracco Imaging SpAInventors: Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Giovanni Battista Giovenzana
-
Patent number: 8871724Abstract: The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3?X1?- (SEQ ID NO: 1), wherein X1 and X1?- are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3? are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterized by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-[L/I/V]-[L/I/V]-[K/R] (SEQ ID NO: 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g., myeloablation.Type: GrantFiled: February 20, 2009Date of Patent: October 28, 2014Assignee: Apim Therapeutics ASInventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
-
Patent number: 8784778Abstract: The present invention relates to a method for the in vivo, ex vivo, or in vitro determination of physical or chemical parameters of diagnostic interest by use of a slow tumbling paramagnetic agent that is responsive to changes of said physical or chemical parameter through changes in the R2p/R1p ratio allowing the determination of the said parameter in a manner that is independent on the actual agent concentration.Type: GrantFiled: April 28, 2006Date of Patent: July 22, 2014Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Enzo Terreno
-
Publication number: 20140186268Abstract: The present invention relates to methods for producing oxide ferrimagnetics with spinel structure and iron oxide nanoparticles by soft mechanochemical synthesis using inorganic salt hydrates, oxide ferrimagnetics with spinel structure and iron oxide nanoparticles of ultra-small size and high specific surface area obtainable by the methods, biocompatible aqueous colloidal systems comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, carriers comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, and uses thereof in medicine.Type: ApplicationFiled: February 4, 2014Publication date: July 3, 2014Applicants: Jozef Stefan Institute, Institute of Strength Physics and Materials Science of Siberian Branch Russian Academy of ScieInventors: Olga VASILJEVA, Volya I. ITIN, Sergey G. PSAKHIE, Georgy A. MIKHAYLOV, Mojca Urska MIKAC, Boris TURK, Anna A. MAGAEVA, Evgeniy P. NAIDEN, Olga G. TEREKHOVA
-
Publication number: 20140178296Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.Type: ApplicationFiled: December 6, 2013Publication date: June 26, 2014Applicant: Georgetown UniversityInventors: Esther H. CHANG, Kathleen F. Pirollo
-
Publication number: 20140161733Abstract: A composition comprising: a liposome having a bilayer structure, a gadofullerene having a high relaxivity, and an amphiphilic receptor ligand. In the composition, the gadofullerene is embedded in the bilayer structure of the liposome. In addition, a method for detecting atherosclerotic plaque in an animal using the composition is described.Type: ApplicationFiled: March 29, 2012Publication date: June 12, 2014Applicant: LUNA INNOVATIONS INCORPORATEDInventors: Zhiguo Zhou, Robert P. Lenk, Christopher L. Kepley
-
Publication number: 20140086846Abstract: A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3, R7, R8, R?1, R?2, R?3, R7? and R8? are selected form hydrogen, a protected C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group; R4, R?4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C1-C3 hydroxyalkyl group, a C1-C3 alkyl group; n is an integer between 0 and 4; R5, R?5 are selected from a hydrogen, a protecting group comprising C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, C2-C30 aromatic radicals, m is an integer between 1 and 10; at least one of R7 and R?7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.Type: ApplicationFiled: September 26, 2012Publication date: March 27, 2014Applicant: GENERAL ELECTRIC COMPANYInventors: Brian James Grimmond, Michael James Rishel, Jeannette Christine Roberts
-
Publication number: 20140044647Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Aeon Medix Inc.Inventors: Yong Song GHO, Yoon Keun Kim, Su Chul Jang, Oh Youn Kim, Dong-Sic Choi, Yae Jin Yoon
-
Patent number: 8636977Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.Type: GrantFiled: March 3, 2006Date of Patent: January 28, 2014Assignee: Bracco Imaging S.p.A.Inventors: Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Carlo Scolastico, Leonardo Manzoni, Daniela Arosio
-
Patent number: 8637028Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.Type: GrantFiled: October 9, 2009Date of Patent: January 28, 2014Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's HospitalInventors: Frank Alexis, Matteo Iannacone, Jinjun Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
-
Patent number: 8617514Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.Type: GrantFiled: October 20, 2006Date of Patent: December 31, 2013Assignee: Georgetown UniversityInventors: Esther H. Chang, Kathleen F. Pirollo
-
Patent number: 8535712Abstract: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.Type: GrantFiled: September 10, 2012Date of Patent: September 17, 2013Assignees: Varian Medical Systems, Inc., Arizona Board of Regents on Behalf of the University of ArizonaInventors: David F. O'Brien, Kathy A. McGovern, Bruce Bondurant, Robert Sutherland
-
Publication number: 20130230457Abstract: The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described.Type: ApplicationFiled: February 15, 2013Publication date: September 5, 2013Applicant: CELSION CORPORATIONInventors: Robert A. REED, Daishui SU
-
Publication number: 20130183234Abstract: Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein.Type: ApplicationFiled: September 26, 2011Publication date: July 18, 2013Applicants: SIEMENS HEALTHCARE DIAGNOSTICS INC, SIEMENS MEDICAL SOLUTIONS USA INCInventors: Les Oppenheimer, Ismayil M. Guracar
-
Publication number: 20130142729Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.Type: ApplicationFiled: January 3, 2013Publication date: June 6, 2013Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITYInventors: The Ohio State University, Immunomedics, Inc.
-
Publication number: 20130129636Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.Type: ApplicationFiled: November 19, 2010Publication date: May 23, 2013Applicants: IMPERIAL INNOVATIONS LIMITED, MEDICAL RESEARCH COUNCILInventors: Nazila Kamaly, Tammy Louise Kalber, Gavin David Kenny, Maya Thanou, Andrew David Miller, Jimmy Bell
-
Patent number: 8440167Abstract: The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque.Type: GrantFiled: October 26, 2009Date of Patent: May 14, 2013Assignee: University of Virginia Patent FoundationInventors: George A. Beller, David K. Glover, Alexander L. Klibanov, Craig H. Meyer, Dayuan Li, Amit Patel, Christopher M. Kramer
-
Patent number: 8361494Abstract: An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a layer surrounding the core particle or a plurality of core particles, the layer includes a phospholipid, (c) an apoprotein associated with the layer, and optionally, (d) a homing molecule associated with at least one of the apoprotein or the phospholipid.Type: GrantFiled: March 6, 2007Date of Patent: January 29, 2013Assignee: The Trustees Of The University of PennsylvaniaInventors: I-Wei Chen, Hoon Choi
-
Publication number: 20130011339Abstract: Bilayer-nanoparticle compositions comprising a nanoparticle core and a lipid bilayer disposed around the exterior surface of the nanoparticle core are provided. In some embodiments, these bilayer-nanoparticle compositions may be dispersed in an aqueous solution. Associated methods are also provided.Type: ApplicationFiled: January 9, 2012Publication date: January 10, 2013Inventors: Vicki Colvin, Arjun Prakash, Huiguang Zhu
-
Patent number: 8349293Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.Type: GrantFiled: March 21, 2008Date of Patent: January 8, 2013Assignee: GuerbetInventor: Claire Corot
-
Publication number: 20120141381Abstract: The invention comprises compositions and methods for loading both magnetic resonance contrast agents and therapeutic agents into liposomes, such as low temperature sensitive liposomes (LTSLs). In certain embodiments, a passive technique is used to load the liposomes. In other embodiments, an active technique is used to load the liposomes. In further embodiments, a magnetic resonance contrast agent and Doxorubicin are loaded into the liposomes. The liposome compositions have higher contrast-agent loadings and are more stable, than those known in the art.Type: ApplicationFiled: February 23, 2010Publication date: June 7, 2012Applicant: Duke University Office of Technology & VentureInventors: Mark W. Dewhirst, Pavel Yarmolenko, Bradford J. Wood, Matthrew R. Dreher, Ayele H. Negussie
-
Publication number: 20120100079Abstract: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least ?18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these.Type: ApplicationFiled: June 25, 2010Publication date: April 26, 2012Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Dirk Burdinski, Jeroen A. Pikkemaat, Bertrand Schmitt, Holger Gruell, Sander Langereis
-
Publication number: 20110286937Abstract: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed.Type: ApplicationFiled: February 18, 2009Publication date: November 24, 2011Applicants: GIFU UNIVERSITY, KATAYAMA CHEMICAL INDUSTRIES CO., LTD.Inventors: Makoto Kiso, Hideharu Ishida, Taiji Yamashita, Koichi Igarashi, Masahiko Hirai
-
Publication number: 20110274625Abstract: Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous centre thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release.Type: ApplicationFiled: November 23, 2009Publication date: November 10, 2011Applicant: MedGenesis Therapeutix ,Inc.Inventors: Thomas Redelmeier, Matthias Luz
-
Patent number: 7998462Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.Type: GrantFiled: October 16, 2007Date of Patent: August 16, 2011Assignee: Kereos, Inc.Inventor: William D. McGhee
-
Patent number: 7906121Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: GrantFiled: April 3, 2009Date of Patent: March 15, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20100254913Abstract: In magnetic resonance imaging (MRI) based on chemical exchange-dependent saturation transfer (CEST), a novel carrier for CEST contrast agents is provided. The carrier is non-spherical and comprises a semipermeable shell, wherein the shell comprises a paramagnetic compound. The shell encloses a cavitycomprising an MR analyte, wherein the semipermeable shell allows diffusion of the MR analyte. The CEST effect is based on the 5 bulk magnetic susceptibility effect caused by the anisotropy of the carrier. This leads to a versatile carrier that does not require interaction of the analyte with a paramgnetic chemical shift reagent.Type: ApplicationFiled: November 21, 2008Publication date: October 7, 2010Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Dirk Burdinski, Sander Langereis, Jeroen Alphons Pikkemaat
-
Patent number: 7769423Abstract: Methods and compositions useful for detecting an in vivo blood pool, monitoring the distribution of a compound of interest to a desired site in an organism by magnetic resonance imaging, monitoring the accumulation of a compound of interest at a desired site in vivo by magnetic resonance imaging, and monitoring the release of liposomal contents to an external stimulus at a desired site in vivo by magnetic resonance imaging are disclosed. Some compositions comprise envirosensitive or non-sensitive liposomes. Contrast agents, such as manganese-based compounds, are also disclosed.Type: GrantFiled: December 29, 2006Date of Patent: August 3, 2010Assignee: Duke UniversityInventors: Benjamin L. Viglianti, Mark W. Dewhirst, Ana M. Ponce
-
Publication number: 20100158817Abstract: The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising an internal and external distribution of magnetic resonance imaging contrast agents.Type: ApplicationFiled: September 21, 2007Publication date: June 24, 2010Inventors: Sigrid L. Fossheim, Esben A, Nilssen
-
Patent number: 7722855Abstract: The invention relates to membrane vesicles from non-pathogenic amoeba, in particular from the amoeba Dictyostelium discoideum, containing a molecule of therapeutic interest, to a method of preparing such vesicles and to the use of said vesicles as a vehicle for transferring the molecule therapeutic interest to an eukaryotic mammalian cell.Type: GrantFiled: July 13, 2004Date of Patent: May 25, 2010Assignee: Universite Pierre et Marie Curie-Paris VIInventors: Irène Tatischeff, Annette Alfsen, Françoise Lavialle
-
Patent number: 7718190Abstract: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.Type: GrantFiled: October 24, 2006Date of Patent: May 18, 2010Inventors: Brian Charles Keller, Danilo Lasic, Alenka Lasic, legal representative
-
Publication number: 20100111876Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.Type: ApplicationFiled: March 21, 2008Publication date: May 6, 2010Applicant: GuerbetInventor: Claire Corot
-
Publication number: 20100061938Abstract: The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising novel combinations of magnetic resonance imaging contrast agents.Type: ApplicationFiled: September 11, 2007Publication date: March 11, 2010Applicant: EPITARGET ASInventors: Sigrid L. Fossheim, Esben A. Nilssen
-
Patent number: 7672704Abstract: Methods and compositions useful for detecting an in vivo blood pool, monitoring the distribution of a compound of interest to a desired site in an organism by magnetic resonance imaging, monitoring the accumulation of a compound of interest at a desired site in vivo by magnetic resonance imaging, and monitoring the release of liposomal contents to an external stimulus at a desired site in vivo by magnetic resonance imaging are disclosed. Some compositions comprise envirosensitive or non-sensitive liposomes. Contrast agents, such as manganese-based compounds, are also disclosed.Type: GrantFiled: September 11, 2003Date of Patent: March 2, 2010Assignee: Duke UniversityInventors: Benjamin L. Viglianti, Mark W. Dewhirst, James R. MacFall, Zeljko Vujaskovic
-
Publication number: 20090311194Abstract: Methods and compositions for using magnetosomes as cellular contrast agents and markers for magnetic resonance imaging are provided. Certain methods involve synthesizing magnetosomes in a cell as directed by a nucleotide construct comprising an exogenous polynucleotide sequence, wherein the magnetosome serves as a contrast agent or marker for magnetic resonance imaging. Methods of synthesizing and isolating magnetosomes for introduction into immune-matched cells within a tissue or subject for use as a contrast agent or marker for magnetic resonance imaging are also provided. Also provided are methods for stably transfecting cells to express a polypeptide that drives or modulates magnetosome production in the cell, cells produced by such methods and methods for their isolation, transgenic animals comprising at least one eukaryotic cell produced by such methods, and vectors and delivery systems for the transfection of such cells.Type: ApplicationFiled: April 28, 2006Publication date: December 17, 2009Applicants: Emory University, Georgia Tech Research CorporationInventors: Xiaoping Philip Hu, Anthony Wing Sang Chan, Omar Zurkiya
-
Patent number: 7618624Abstract: A method for regulating the body weight of an animal by feeding it a liposome-encapsulated antibody against lipase.Type: GrantFiled: January 7, 1999Date of Patent: November 17, 2009Assignees: Anitox CorporationInventor: Julio Pimentel
-
Publication number: 20090274630Abstract: Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo.Type: ApplicationFiled: March 16, 2009Publication date: November 5, 2009Applicant: National Health Research InstitutesInventor: Dong-Ming HUANG
-
Patent number: RE45195Abstract: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.Type: GrantFiled: February 15, 2013Date of Patent: October 14, 2014Assignees: Marval Pharma, Inc., Case Western Reserve University, Cleveland State UniversityInventors: Ananth Annapragada, Ravi V. Bellamkonda, Eric Hoffman, Chandra Vijayalakshmi, Chen-Yu Kao